Retraction: Efficacy of ketamine in bipolar depression: Systematic review and meta-analysis (Journal of Psychiatric Practice (2015) 21 (427-435) DOI: 10.1097/PRA.0000000000000106);Efficacy of ketamine in bipolar depression: Systematic review and meta-analysis

Journal of Psychiatric Practice

Volumn 21, Issue 6, 2015, Pages 427-435

  Parsaik, Ajay K ^a   Singh, Balwinder ^b,c   Khosh Chashm, Darrow ^a   Mascarenhas, Soniya S ^d  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^b UND School of Medicine & Health Sciences Southeast Campus   (United States)

^c MAYO CLINIC   (United States)

^d London Training College   (United Kingdom)

Author keywords

Anhedonia; Bipolar depression; Ketamine; Suicidal ideation

Indexed keywords

KETAMINE; AMINO ACID RECEPTOR BLOCKING AGENT;

AGITATION; ANHEDONIA; ANXIETY DISORDER; ARTHRALGIA; BIPOLAR DEPRESSION; BIPOLAR I DISORDER; BIPOLAR II DISORDER; BLURRED VISION; BONE PAIN; COCHRANE LIBRARY; COGNITIVE DEFECT; DIZZINESS; DROWSINESS; DRUG EFFICACY; DRUG INDUCED HEADACHE; ELEVATED BLOOD PRESSURE; EMBASE; FAINTNESS; FEAR; FLATULENCE; HUMAN; IRRITABILITY; LETHARGY; MEDLINE; META ANALYSIS; MYALGIA; NAUSEA; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SCOPUS; SEDATION; SLEEP DISORDER; SUICIDAL IDEATION; SYSTEMATIC REVIEW; TACHYCARDIA; XEROSTOMIA; ADULT; BIPOLAR DISORDER; DRUG EFFECTS; FEMALE; MALE; MIDDLE AGED; PSYCHOLOGY; TREATMENT OUTCOME;

ADULT; ANHEDONIA; BIPOLAR DISORDER; EXCITATORY AMINO ACID ANTAGONISTS; FEMALE; HUMANS; KETAMINE; MALE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SUICIDAL IDEATION; TREATMENT OUTCOME;

EID: 84947275548     PISSN: 15274160     EISSN: None     Source Type: Journal    
DOI: 10.1097/PRA.0000000000000324     Document Type: Erratum

References (28)

1. Nock MK, Hwang I, Sampson N, et al. Cross-national analysis of the associations among mental disorders and suicidal behavior: findings from the WHO World Mental Health Surveys. PLoS Med. 2009;6:e1000123.
2. Nordentoft M, Mortensen PB, Pedersen CB. Absolute risk of suicide after first hospital contact in mental disorder. Arch Gen Psychiatry. 2011;68:1058-1064.
3. Calabrese JR, Huffman RF, White RL, et al. Lamotrigine in the acute treatment of bipolar depression: results of five double-blind, placebo-controlled clinical trials. Bipolar Disord. 2008;10:323-333.
4. Merikangas KR, Akiskal HS, Angst J, et al. Lifetime and 12-month prevalence of bipolar spectrum disorder in the National Comorbidity Survey replication. Arch Gen Psychiatry. 2007;64:543-552.
5. Diazgranados N, Ibrahim L, Brutsche NE, et al. A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression. Arch Gen Psychiatry. 2010;67:793-802.
6. Post RM, Leverich GS, Altshuler LL, et al. Differential clinical characteristics, medication usage, and treatment response of bipolar disorder in the US versus The Netherlands and Germany. Int Clin Psychopharmacol. 2011;26:96-106.
7. Jick H, Kaye JA, Jick SS. Antidepressants and the risk of suicidal behaviors. JAMA. 2004;292:338-343.
8. Machado-Vieira R, Salvadore G, Luckenbaugh DA, et al. Rapid onset of antidepressant action: a new paradigm in the research and treatment of major depressive disorder. J Clin Psychiatry. 2008;69:946-958.
9. Aan Het Rot M, Zarate CA Jr, Charney DS, et al. Ketamine for depression: where do we go from here? Biol Psychiatry. 2012;72:537-547.
10. Autry AE, Adachi M, Nosyreva E, et al. NMDA receptor blockade at rest triggers rapid behavioral antidepressant responses. Nature. 2011;475:91-95.
11. Li N, Lee B, Liu RJ, et al. mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science. 2010;329:959-964.
12. Maeng S, Zarate CA Jr, Du J, et al. Cellular mechanisms underlying the antidepressant effects of ketamine: role of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors. Biol Psychiatry. 2008;63:349-352.
13. Zarate CA Jr, Brutsche NE, Ibrahim L, et al. Replication of ketamine's antidepressant efficacy in bipolar depression: a randomized controlled add-on trial. Biol Psychiatry. 2012;71:939-946.
14. Kapur S, Seeman P. Ketamine has equal affinity for NMDA receptors and the high-affinity state of the dopamine D2 receptor. Biol Psychiatry. 2001;49:954-957.
15. Kapur S, Seeman P. NMDA receptor antagonists ketamine and PCP have direct effects on the dopamine D(2) and serotonin 5-HT(2)receptors-implications for models of schizophrenia. Mol Psychiatry. 2002;7:837-844.
16. Vollenweider FX, Vontobel P, Oye I, et al. Effects of (S)-ketamine on striatal dopamine: a [11C] raclopride PET study of a model psychosis in humans. J Psychiatr Res. 2000;34:35-43.
17. Murrough JW, Iosifescu DV, Chang LC, et al. Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial. Am J Psychiatry. 2013;170:1134-1142.
18. Welch JS. Evidence supports safe use of povidone-iodine. Oncol Nurs Forum. 1991;18:659-660.
19. Zarate CA Jr, Singh JB, Carlson PJ, et al. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry. 2006;63:856-864.
20. Cohen J. Coefficient of agreement for nominal scales educational and psychological measurement. Educ Psychol Meas. 1960;20:37-46.
21. Higgins JPT, Greene S, eds. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0. The Cochrane Collaboration. Available at Error! Hyperlink reference not valid. Accessed November 18, 2014.
22. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177-188.
23. Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557-560.
24. Lally N, Nugent AC, Luckenbaugh DA, et al. Anti-anhedonic effect of ketamine and its neural correlates in treatment-resistant bipolar depression. Transl Psychiatry. 2014;4:e469.
25. Lara DR, Bisol LW, Munari LR. Antidepressant, mood stabilizing and procognitive effects of very low dose sub-lingual ketamine in refractory unipolar and bipolar depression. Int J Neuropsychopharmacol. 2013;16:2111-2117.
26. Permoda-Osip A, Skibinska M, Bartkowska-Sniatkowska A, et al. Factors connected with efficacy of single ketamine infusion in bipolar depression. Psychiatr Pol. 2014;48:35-47.
27. Fond G, Loundou A, Rabu C, et al. Ketamine administration in depressive disorders: a systematic review and meta-analysis. Psychopharmacology (Berl). 2014;231: 3663-3676.
28. Sterne JA, Gavaghan D, Egger M. Publication and related bias in meta-analysis: power of statistical tests and prevalence in the literature. J Clin Epidemiol. 2000; 53:1119-1129.